XML 66 R56.htm IDEA: XBRL DOCUMENT v3.21.2
License Funding and Other Agreements Related to the CVR - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2020
Feb. 28, 2021
Nov. 30, 2020
May 31, 2019
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2021
Mar. 23, 2017
Research And Development Arrangement Contract To Perform For Others [Line Items]                
Exercised Investment Right and Purchased             $ 10,000,000.0  
Estimated fair value of the CVR liability         $ 0   0  
Funding Agreement                
Research And Development Arrangement Contract To Perform For Others [Line Items]                
Qualifying expenses             300,000  
National Institute of Health                
Research And Development Arrangement Contract To Perform For Others [Line Items]                
Grant term       5 years        
Grants receivable       $ 1,500,000        
Qualifying expenses         36,000      
Qualifying expenses on cumulative basis             1,300,000  
National Institute of Health | Funding Agreement                
Research And Development Arrangement Contract To Perform For Others [Line Items]                
Qualifying expenses           $ 0 500,000  
Qualifying expenses on cumulative basis             1,300,000  
Contingent Value Rights Agreement | C O V I D19                
Research And Development Arrangement Contract To Perform For Others [Line Items]                
Total fees and expenses related to clinical trials $ 1,100,000           3,000,000.0  
Post Exposure Prophylaxis in adults   In February 2021, management terminated the National Institute on Aging study of RTB101 for COVID-19 post-exposure prophylaxis in adults age 65 years and older due to poor enrollment            
Increase decrease in estimated fair value of CVR liability     $ 400,000          
Estimated fair value of the CVR liability     $ 600,000   $ 0   $ 0  
Novartis License Agreement | Novartis International Pharmaceutical Ltd.                
Research And Development Arrangement Contract To Perform For Others [Line Items]                
License agreement termination description             The agreement may be terminated by either party upon a material breach of obligation by the other party that is not cured with 60 days after written notice. resTORbio may terminate the agreement in its entirety or on a product-by-product or country-by-country basis with or without cause with 60 days’ prior written notice.  
Novartis License Agreement | Novartis International Pharmaceutical Ltd. | Maximum                
Research And Development Arrangement Contract To Perform For Others [Line Items]                
Aggregate amount payable upon satisfaction of clinical milestones               $ 4,300,000
Aggregate amount payable upon satisfaction of regulatory milestones for first indication approved               24,000,000
Aggregate amount payable upon satisfaction of regulatory milestones for second indication approved               18,000,000
Aggregate amount payable upon satisfaction of commercial milestones               $ 125,000,000